TELECONFERENCE MEETING OF THE
ADVISORY COMMITTEE ON THE
MEDICAL USES OF ISOTOPES

October 18, 2011

MEETING SUMMARY

PURPOSE

To discuss the Advisory Committee on the Medical Uses of Isotopes (ACMUI) Permanent Implant Brachytherapy Subcommittee Report as it relates to the implementation of the medical regulations in 10 Code of Federal Regulations (CFR) Part 35, "Medical Use of Byproduct Material."

OUTCOME

The ACMUI Permanent Implant Brachytherapy Subcommittee (PIBS) provided a draft report for the ACMUI's consideration. The PIBS made recommendations to revise the report, and the revisions were unanimously approved. The PIBS draft report was endorsed by the full ACMUI. The U.S. Nuclear Regulatory Commission (NRC) staff gained a better understanding of the views and opinions of the ACMUI, as well as other stakeholders' views and opinions. The staff will consider these views in its continuing effort to make 10 CFR Part 35 more useful, practical, and not overly burdensome on licensees, while maintaining public health and safety.

Full transcripts of the ACMUI meeting can be found on NRC's public website:
http://www.nrc.gov/reading-rm/doc-collections/acmui/tr/

Handouts from the ACMUI meeting can be found on NRC's public website:
http://www.nrc.gov/reading-rm/doc-collections/acmui/meeting-slides/

Final ACMUI Permanent Implant Brachytherapy Report can be found on NRC's public website under "Related Information": http://www.nrc.gov/about-nrc/regulatory/advisory/acmui.html

ATTENDEES

ACMUI

Milton S. Guiberteau, M.D.	Member
Susan M. Langhorst, Ph.D.	Member
Leon S. Malmud, M.D.	Chairman
Steve R. Mattmuller	Member
Christopher J. Palestro, M.D.	Member
John H. Suh, M.D.	Member
Orhan H. Suleiman, Ph.D.	Member
Bruce R. Thomadsen Ph.D.	Vice Chairman
William A. Van Decker, M.D.	Member
Laura Weil	Member
James S. Welsh, M.D.	Member
Pat Zanzonico, Ph.D	Member

NRC

Cynthia Carpenter	Acting Director, Office of Federal and State Materials and Environmental Management Programs
Brian McDermott	Director, Division of Materials Safety and State Agreements
Chris Einberg	Designated Federal Officer
Michael Fuller	Alternate Designated Federal Officer
Ashley Cockerham	Alternate Designated Federal Officer and ACMUI Coordinator
Neelam Bhalla	NRC staff
Susan Chidakel	NRC staff
Said Daibes, Ph.D.	NRC staff
Donna-Beth Howe, Ph.D.	NRC staff
Edward Lohr	NRC staff
Gretchen Rivera-Capella	NRC staff
Ronald Zelac, Ph.D.	NRC staff

MEMBERS OF THE PUBLIC:

Darice Bailey	Texas Department of State Health Services
Keith Brown	University of Pennsylvania
Joseph Buckles	Hays Companies
Robert Dansereau	New York State Department of Health
William Davidson	University of Pennsylvania
Lynne Fairobent	American Association of Physicists in Medicine
Michael Hagan, M.D.	Veterans Health Administration
Thomas Huston, M.D.	Veterans Health Administration
John Kent	Indiana University-Purdue University Indianapolis
Karen Langley	University of Utah
Janette Merill	Society of Nuclear Medicine
Michael Peters	American College of Radiology
Raymond Poston	Kentucky Radiation Health
Gloria Romanelli	American College of Radiology
Mack Richard	Indiana University-Purdue University Indianapolis
Joseph Rodgers	Theragenics Corporation
Cindy Tomlinson	American Society for Radiation Oncology

AGENDA TOPICS

1. Permanent Implant Brachytherapy Subcommittee report

RECOMMENDATIONS AND ACTIONS

The subcommittee made the following changes to the draft report show in italics below:

Page 1, "Recommendations" A.1.a.(i) ~~*Greater than*~~ 20% *or more* of the of the sources fall outside of the intended locations (planning target volume, PTV).

Page 1, "Recommendations" A.1.b. Calculated dose to 90% of the clinical target volume (CTV) is less than 60% of the dose prescribed to the CTV (D_{90}<60%) *within a time frame to be determined*

by the Authorized User consistent with prevailing medical practice but not to exceed 60 days unless accompanied by written justification.

Page 2, "Recommendations" A.3.

a. Using the wrong radionuclide;
b. *Using the wrong activity or source strength (+/- 20%) as specified in the written directive;*
c. Delivered to the wrong patient;
d. Delivered directly to the wrong site or body part;
e. Delivered using the wrong modality or
f. Using leaking sources,

with the exception of seed migration, edema, and other patient-related factors or source displacement following placement, as long as the criteria in 1.a.(i) is not violated.

Page 2, "Terminology" D_{90} – The *minimum* dose to 90% of the CTV

The changes above were unanimously approved by the Permanent Implant Brachytherapy Subcommittee, and the Permanent Implant Brachytherapy Subcommittee Report was unanimously approved by the full ACMUI.